button bars forest bayes pooled summary circles
 
DCR

mGC or mGEJC - L1 - HER2 neg/PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - HER2 neg/PDL1 positive

versus Standard of Care (SoC)
nivolumab plus SoC vs. Standard of Care (SoC) 2 -

mGC or mGEJC - L1 - HER2 negative metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - HER2 negative

versus Standard of Care (SoC)
nivolumab plus SoC vs. Standard of Care (SoC) 1 -

mGC or mGEJC - L1 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - PDL1 positive

versus placebo plus SoC
pembrolizumab alone vs. placebo plus SoC 1 -
pembrolizumab plus SoC vs. placebo plus SoC 2 -
versus Standard of Care (SoC)
pembrolizumab alone vs. Standard of Care (SoC) 1 -

mGC or mGEJC - L2 - all population metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - all population

versus paclitaxel
avelumab alone vs. paclitaxel 1 0.37 [0.23; 0.60], 1 RCT, I2=0%
statistically significant harm
pembrolizumab alone vs. paclitaxel 1 -
versus placebo
nivolumab alone vs. placebo 1 1.99 [1.24; 3.18], 1 RCT, I2=0%
unassessable degree of certainty

mGC or mGEJC - L2 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - PDL1 positive

versus paclitaxel
pembrolizumab alone vs. paclitaxel 1 -

mGC or mGEJC - M - HER2 negative metastatic/advanced mGC or mGEJC mGC or mGEJC - maintenance (M) mGC or mGEJC - M - HER2 negative

versus Standard of Care (SoC)
avelumab alone vs. Standard of Care (SoC) 1 0.62 [0.43; 0.89], 1 RCT, I2=0%
statistically significant harm

mGC or mGEJC - M - HER2 neg/PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - maintenance (M) mGC or mGEJC - M - HER2 neg/PDL1 positive

versus Standard of Care (SoC)
avelumab alone vs. Standard of Care (SoC) 1 -

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons